Share Twitter LinkedIn Facebook Email Jeanny B. Aragon-Ching, MD, FACP, discusses the 2nd line treatment options in RCC after I-O failure at Annual Meeting 2018.
Genitourinary Cancer [2025] Treatment Breakthroughs: ASCO GU 2025 Highlights Nataliya Mar, MD – MOASC Genitourinary 6 Mins Read
Tivozanib for RCC: Unpacking Efficacy, Safety, and Dose Optimization – Bradley McGregor, MD – Dana Farber Genitourinary 3 Mins Read
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI Kidney 3 Mins Read